Other languages Theratechnologies Inc.

Equities

TH

CA88338H7040

Market Closed - Toronto S.E. Other stock markets 21:00:00 26/04/2024 BST			5-day change	1st Jan Change
1.8 ^CAD	0.00%		-0.55%	-15.89%

04-10	Update On Theratechnologies; Down More Than 5% On TSX As Q1 Net Loss Narrows, Awaits FDA Decision	MT
04-10	Theratechnologies Up Near 6% In US Premarket As Q1 Net Loss Narrows, Accelerates Phase 1 Trial of Ovarian Cancer Drug	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Update On Theratechnologies; Down More Than 5% On TSX As Q1 Net Loss Narrows, Awaits FDA Decision	04-10
Theratechnologies Up Near 6% In US Premarket As Q1 Net Loss Narrows, Accelerates Phase 1 Trial of Ovarian Cancer Drug	04-10
Theratechnologies Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024	04-10
Theratechnologies Inc. Re-Affirms Earnings Guidance for the Fiscal Year 2024	04-10
Theratechnologies Inc. Preclinical Data Presentation At AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology? Oncology Platform	04-08
Theratechnologies Inc. Appoints Elina Tea to its Board of Directors and as Member of the Company's Audit Committee	04-05
Theratechnologies To Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology Platform	03-28
Theratechnologies Inc. Announces That It Will Phase Down Its Preclinical Oncology Research Activities	03-22
Theratechnologies to Phase Down Preclinical Oncology Research Program	03-22
Theratechnologies Inc. Appoints Jordan Zwick to Its Board of Directors and as Member of the Audit Committee	03-21
Theratechnologies Inc. Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer	03-21
Theratechnologies Inc. Announces Board Changes	02-29
Theratechnologies Down 30% In US Premarket -- Receives Refusal To File Letter From FDA	02-27
Theratechnologies Inc. Receives Refusal to File Letter for Trogarzo Intramuscular Method of Administration sBLA from FDA	02-27
Theratechnologies Reports Record Quarterly Revenue of US$23.5 Million, Q4 Net Loss of $0.08 Per Share	02-21
Theratechnologies Inc. Reports Earnings Results for the Full Year Ended November 30, 2023	02-21
Theratechnologies Inc. Provides Earnings Guidance for the Year 2024	02-21
Theratechnologies Inc. Announces Publication in Frontiers in Immunology That Deepens Understanding of Sudocetaxel Zendusortide Molecular Mechanism of Action	02-20
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer	02-15
Theratechnologies Inc. Receives Complete Response Letter from the FDA for the F8 Formulation of Tesamorelin sBLA	01-24

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Theratechnologies Inc.

Equities

TH

CA88338H7040

Other languages

Filters